SOLENO THERAPEUT. DL-001 Market Cap ($2.31 Billion)
Market Cap & Net Worth: SOLENO THERAPEUT. DL-001 (6XC)
SOLENO THERAPEUT. DL-001 market cap. SOLENO THERAPEUT. DL-001 (F:6XC) has a market capitalization of $2.31 Billion (€1.97 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #5498 globally and #877 in its home market, demonstrating a 1.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOLENO THERAPEUT. DL-001's stock price €44.86 by its total outstanding shares 52120147 (52.12 Million). Also see SOLENO THERAPEUT. DL-001 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
SOLENO THERAPEUT. DL-001 Market Cap History (2019–2026)
SOLENO THERAPEUT. DL-001 market cap history from 2019 to 2026. Data shows growth from $143.80 Million to $2.73 Billion (60.30% CAGR). Check 6XC share price today for real-time trading data and today's change.
SOLENO THERAPEUT. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOLENO THERAPEUT. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of SOLENO THERAPEUT. DL-001 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
12.62x
SOLENO THERAPEUT. DL-001's market cap is 12.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
114.98x
SOLENO THERAPEUT. DL-001's market cap is 114.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $2.40 Billion | $190.41 Million | $20.89 Million | 12.62x | 114.98x |
Competitor Companies of 6XC by Market Capitalization
Companies near SOLENO THERAPEUT. DL-001 in the global market cap rankings as of November 4, 2026. Also see total assets of SOLENO THERAPEUT. DL-001 for a full breakdown of the balance sheet.
Key companies related to SOLENO THERAPEUT. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of SOLENO THERAPEUT. DL-001 (2019–2026)
Market capitalization of SOLENO THERAPEUT. DL-001 from 2019 to today. Between 2019 and today, SOLENO THERAPEUT. DL-001's market cap moved from $143.80 Million to $ 2.73 Billion, with a yearly change of 60.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.73 Billion | +13.80% |
| 2025 | €2.40 Billion | -5.96% |
| 2024 | €2.55 Billion | +101.54% |
| 2023 | €1.27 Billion | +1068.54% |
| 2022 | €108.46 Million | +358.76% |
| 2021 | €23.64 Million | -74.13% |
| 2020 | €91.40 Million | -36.44% |
| 2019 | €143.80 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of SOLENO THERAPEUT. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.31 Billion USD |
| MoneyControl | $2.31 Billion USD |
| MarketWatch | $2.31 Billion USD |
| marketcap.company | $2.31 Billion USD |
| Reuters | $2.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more